T 2077/18 (Unitary pharmaceutical dosage form/GILEAD) of 13.01.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T207718.20220113
- Date of decision
- 13 January 2022
- Case number
- T 2077/18
- Petition for review of
- -
- Application number
- 11167101.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Unitary pharmaceutical dosage form comprising Tenofovir DF
- Applicant name
- Gilead Sciences, LLC
- Opponent name
- KELTIE LLP
Sandoz AG
Accord Healthcare Ltd
Hetero Drugs Ltd. - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention R 103(1)(a)European Patent Convention R 111(2)Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Reimbursement of the appeal fees - No
Admission of documents
Main request - Inventive step (No)
Auxiliary requests 1-3, 3A - Inventive step (No)
Auxiliary requests 4A, 4, 4B - Extension of the subject-matter (Yes)
Auxiliary request 5 - Inventive step (No)
Auxiliary request 6 - Extension of the subject-matter (Yes) - Catchword
- -
- Cited cases
- T 1742/12
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.